About: http://data.cimple.eu/news-article/f725a399a4f044d1279038c2afa7853821a0381d88c3453dd22e70ae

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/f725a399a4f044d1279038c2afa7853821a0381d88c3453dd22e70ae Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Canadian researchers launched a study Monday into the use of a powerful anti-inflammatory drug to reduce the risks of pulmonary complications and death related to the new coronavirus. Several COVID-19 patients have had severe complications from a surge of activated immune cells in the lungs -- known as a "cytokine storm." In a cytokine storm, the immune system overreacts and damages lung tissue, leading to acute respiratory distress and multi-organ failure. A team led by Jean-Claude Tardif, director of the Montreal Heart Institute research center and professor of medicine at the University of Montreal are hoping the drug colchicine will work to moderate the overproduction of immune cells and their activating compounds -- called cytokines -- in COVID-19 patients. If it proves to be successful, the drug -- which is already used to treat gout and pericarditis (inflammation of the heart membrane), and is readily available and inexpensive -- could become a key tool in the pandemic fight. Tardiff told public broadcaster Radio-Canada that he hopes to know if it works within three months. He said he became interested in its possible application as a COVID-19 fighter when it became clear that most children were resistant to the illness. Children typically have reduced inflammatory responses to colds and flus, compared to adults. In laboratory tests, animals whose inflammatory responses were blocked also lived longer when exposed to influenza. One hundred and 25 people worked on the hypothesis and Health Canada approved the Quebec government-funded study within 24 hours. According to a heart institute statement, the researchers are looking to recruit 6,000 Canadians with the coronavirus, for a clinical trial. There were 1,430 cases of COVID-19 confirmed in Canada as of 2200 GMT Sunday, including 20 deaths. amc/jm
schema:headline	Researchers study drug to reduce COVID-19 complications
schema:mentions	Cell membrane Pulmonary edema Cytokine release syndrome Shortness of breath Health Canada Pericarditis Gout Inflammation USA Gymnastics Clinical trial Canadian Broadcasting Corporation Medication Montreal Quebec Immune system Fighter aircraft Influenza Canada Pandemic Coronavirus Coronavirus disease 2019 Montreal Heart Institute Colchicine Multiple organ dysfunction syndrome Overproduction Cytokine Greenwich Mean Time
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-03-23 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	85 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software